Revisiting immune-based therapies for aggressive follicular cell-derived thyroid cancers

Thyroid

Volumn 23, Issue 5, 2013, Pages 529-542

  French, Jena D ^a,b  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF COLORADO CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARLUMAB; CETUXIMAB; CLODRONIC ACID; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DABRAFENIB; DACLIZUMAB; DENILEUKIN DIFTITOX; GLYCOPROTEIN GP 100 VACCINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; IMATINIB; INTERLEUKIN 10; INTERLEUKIN 2; IPILIMUMAB; NIVOLUMAB; PANITUMUMAB; PROGRAMMED DEATH 1 RECEPTOR; SIPULEUCEL T; STEROID; SUNITINIB; THYROGLOBULIN; THYROID ANTIBODY; THYROID PEROXIDASE; THYROTROPIN RECEPTOR; TOSITUMOMAB I 131; TRABECTEDIN; TRANSFORMING GROWTH FACTOR BETA; TRASTUZUMAB; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG; VACCINE;

ADAPTIVE IMMUNITY; ANTIGEN PRESENTATION; ANTIGEN RECOGNITION; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER SURVIVOR; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL INFILTRATION; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; EXTRACELLULAR MATRIX; FOLLICULAR CELL DERIVED THYROID CANCER; HELPER CELL; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; IN VITRO STUDY; INFLAMMATION; MACROPHAGE; MAST CELL; METASTASIS; NATURAL KILLER CELL; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; TH1 CELL; TH17 CELL; TH2 CELL; THYROID CANCER; TREATMENT OUTCOME; TUMOR CELL; TUMOR MICROENVIRONMENT; UNSPECIFIED SIDE EFFECT;

ADAPTIVE IMMUNITY; ADENOCARCINOMA, FOLLICULAR; ANIMALS; HUMANS; IMMUNITY, CELLULAR; IMMUNOMODULATION; LYMPHATIC METASTASIS; THYROID NEOPLASMS;

EID: 84880564632     PISSN: 10507256     EISSN: 15579077     Source Type: Journal    
DOI: 10.1089/thy.2012.0566     Document Type: Review

References (140)

1. Amino N, Pysher T, Cohen EP, Degroot LJ 1975 Immunologic aspects of human thyroid cancer. Humoral and cell-mediated immunity, and a trial of immunotherapy. Cancer 36:963-973.
2. Howlader N NA, Krapcho M, Neyman N, Aminou R, Waldron W, Altekruse SF, Kosary CL, Ruhl J, Tatalovich Z, Cho H, Mariotto A, Eisner MP, Lewis DR, Chen HS, Feuer EJ, Cronin KA, Edwards BK (eds) Posted to the SEER web site, 2011 Surveillance Epidemiology and End Results (SEER): Cancer Statistics Review 1975-2008. Available at http://seer. cancer. gov/csr/1975-2008, based on November 2010 SEER data submission. National Cancer Institute, Bethesda, MD.
3. Mazzaferri EL, Jhiang SM 1994 Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 97:418-428.
4. Nagaiah G, Hossain A, Mooney CJ, Parmentier J, Remick SC 2011 Anaplastic thyroid cancer: a review of epidemiology, pathogenesis, and treatment. J Oncol 2011:542358.
5. Erlich P 1909 Ueber den jetzigen stand der Karzinomforschung. Ned Tijdschr Tandheelkd 5:273-290.
6. Burnet FM 1970 The concept of immunological surveillance. Prog Exp Tumor Res 13:1-27.
7. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD 2002 Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 3:991-998.
8. Hanahan D, Weinberg RA 2011 Hallmarks of cancer: the next generation. Cell 144:646-674.
9. Zhou G, Drake CG, Levitsky HI 2006 Amplification of tumor-specific regulatory T cells following therapeutic cancer vaccines. Blood 107:628-636.
10. Bogen B 1996 Peripheral T cell tolerance as a tumor escape mechanism: deletion of CD4+ T cells specific for a monoclonal immunoglobulin idiotype secreted by a plasmacytoma. Eur J Immunol 26:2671-2679.
11. Staveley-O'Carroll K, Sotomayor E, Montgomery J, Borrello I, Hwang L, Fein S, Pardoll D, Levitsky H 1998 Induction of antigen-specific T cell anergy: an early event in the course of tumor progression. Proc Natl Acad Sci USA 95:1178-1183.
12. Willimsky G, Blankenstein T 2005 Sporadic immunogenic tumours avoid destruction by inducing T-cell tolerance. Nature 437:141-146.
13. Sotomayor EM, Borrello I, Tubb E, Rattis FM, Bien H, Lu Z, Fein S, Schoenberger S, Levitsky HI 1999 Conversion of tumor-specific CD4+ T-cell tolerance to T-cell priming through in vivo ligation of CD40. Nat Med 5:780-787.
14. Lee PP, Yee C, Savage PA, Fong L, Brockstedt D, Weber JS, Johnson D, Swetter S, Thompson J, Greenberg PD, Roederer M, Davis MM 1999 Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat Med 5:677-685.
15. Ahmadzadeh M, Johnson LA, Heemskerk B, Wunderlich JR, Dudley ME, White DE, Rosenberg SA 2009 Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood 114:1537-1544.
16. Fourcade J, Sun Z, Benallaoua M, Guillaume P, Luescher IF, Sander C, Kirkwood JM, Kuchroo V, Zarour HM 2010 Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients. J Exp Med 207:2175-2186.
17. Fourcade J, Sun Z, Pagliano O, Guillaume P, Luescher IF, Sander C, Kirkwood JM, Olive D, Kuchroo V, Zarour HM 2012 CD8+ T cells specific for tumor antigens can be rendered dysfunctional by the tumor microenvironment through upregulation of the inhibitory receptors BTLA and PD-1. Cancer Res 72:887-896.
18. Matsuzaki J, Gnjatic S, Mhawech-Fauceglia P, Beck A, Miller A, Tsuji T, Eppolito C, Qian F, Lele S, Shrikant P, Old LJ, Odunsi K 2010 Tumor-infiltrating NY-ESO-1-specific CD8 + T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer. Proc Natl Acad Sci USA 107:7875-7880.
19. Kim PS, Ahmed R 2010 Features of responding T cells in cancer and chronic infection. Curr Opin Immunol 22:223-230.
20. Jin HT, Jeong YH, Park HJ, Ha SJ 2011 Mechanism of T cell exhaustion in a chronic environment. BMB Rep 44:217-231.
21. Rabinovich GA, Gabrilovich D, Sotomayor EM 2007 Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol 25:267-296.
22. Groh V, Wu J, Yee C, Spies T 2002 Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 419:734-738.
23. Cuenca A, Cheng F, Wang H, Brayer J, Horna P, Gu L, Bien H, Borrello IM, Levitsky HI, Sotomayor EM 2003 Extralymphatic solid tumor growth is not immunologically ignored and results in early induction of antigen-specific T-cell anergy: dominant role of cross-tolerance to tumor antigens. Cancer Res 63:9007-9015.
24. Sotomayor EM, Borrello I, Rattis FM, Cuenca AG, Abrams J, Staveley-O'Carroll K, Levitsky HI 2001 Cross-presentation of tumor antigens by bone marrow-derived antigenpresenting cells is the dominant mechanism in the induction of T-cell tolerance during B-cell lymphoma progression. Blood 98:1070-1077.
25. Gabrilovich D 2004 Mechanisms and functional significance of tumour-induced dendritic-cell defects. Nat Rev Immunol 4:941-952.
26. Chaux P, Favre N, Martin M, Martin F 1997 Tumorinfiltrating dendritic cells are defective in their antigenpresenting function and inducible B7 expression in rats. Int J Cancer 72:619-624.
27. Sica A, Larghi P, Mancino A, Rubino L, Porta C, Totaro MG, Rimoldi M, Biswas SK, Allavena P, Mantovani A 2008 Macrophage polarization in tumour progression. Semin Cancer Biol 18:349-355.
28. Thomas DA, Massague J 2005 TGF-beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance. Cancer Cell 8:369-380.
29. Kurte M, Lopez M, Aguirre A, Escobar A, Aguillon JC, Charo J, Larsen CG, Kiessling R, Salazar-Onfray F 2004 A synthetic peptide homologous to functional domain of human IL-10 down-regulates expression of MHC class I and Transporter associated with Antigen Processing 1/2 in human melanoma cells. J Immunol 173:1731-1737.
30. Zou W 2006 Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol 6:295-307.
31. Bates GJ, Fox SB, Han C, Leek RD, Garcia JF, Harris AL, Banham AH 2006 Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J Clin Oncol 24: 5373-5380.
32. Carreras J, Lopez-Guillermo A, Fox BC, Colomo L, Martinez A, Roncador G, Montserrat E, Campo E, Banham AH 2006 High numbers of tumor-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma. Blood 108:2957-2964.
33. Deng L, Zhang H, Luan Y, Zhang J, Xing Q, Dong S, Wu X, Liu M, Wang S 2010 Accumulation of foxp3 + T regulatory cells in draining lymph nodes correlates with disease progression and immune suppression in colorectal cancer patients. Clin Cancer Res 16:4105-4112.
34. Nakamura R, Sakakibara M, Nagashima T, Sangai T, Arai M, Fujimori T, Takano S, Shida T, Nakatani Y, Miyazaki M 2009 Accumulation of regulatory T cells in sentinel lymph nodes is a prognostic predictor in patients with nodenegative breast cancer. Eur J Cancer 45:2123-2131.
35. Wolf D, Wolf AM, Rumpold H, Fiegl H, Zeimet AG, Muller-Holzner E, Deibl M, Gastl G, Gunsilius E, Marth C 2005 The expression of the regulatory T cell-specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer. Clin Cancer Res 11:8326-8331.
36. Pardoll DM 2012 The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12:252-264.
37. Tivol EA, Borriello F, Schweitzer AN, Lynch WP, Bluestone JA, Sharpe AH 1995 Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruc-tion, revealing a critical negative regulatory role of CTLA-4. Immunity 3:541-547.
38. Waterhouse P, Penninger JM, Timms E, Wakeham A, Shahinian A, Lee KP, Thompson CB, Griesser H, Mak TW 1995 Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science 270:985-988.
39. Vibhakar R, Juan G, Traganos F, Darzynkiewicz Z, Finger LR 1997 Activation-induced expression of human programmed death-1 gene in T-lymphocytes. Exp Cell Res 232:25-28.
40. Francisco LM, Sage PT, Sharpe AH 2010 The PD-1 pathway in tolerance and autoimmunity. Immunol Rev 236: 219-242.
41. Wherry EJ, Ha SJ, Kaech SM, Haining WN, Sarkar S, Kalia V, Subramaniam S, Blattman JN, Barber DL, Ahmed R 2007 Molecular signature of CD8+ T cell exhaustion during chronic viral infection. Immunity 27:670-684.
42. Hamanishi J, Mandai M, Iwasaki M, Okazaki T, Tanaka Y, Yamaguchi K, Higuchi T, Yagi H, Takakura K, Minato N, Honjo T, Fujii S 2007 Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci USA 104:3360-3365.
43. Thompson RH, Kuntz SM, Leibovich BC, Dong H, Lohse CM, Webster WS, Sengupta S, Frank I, Parker AS, Zincke H, Blute ML, Sebo TJ, Cheville JC, Kwon ED 2006 Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res 66:3381-3385.
44. Francisco LM, Salinas VH, Brown KE, Vanguri VK, Freeman GJ, Kuchroo VK, Sharpe AH 2009 PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J Exp Med 206:3015-3029.
45. Wing K, Onishi Y, Prieto-Martin P, Yamaguchi T, Miyara M, Fehervari Z, Nomura T, Sakaguchi S 2008 CTLA-4 control over Foxp3 + regulatory T cell function. Science 322:271-275.
46. Blank C, Brown I, Peterson AC, Spiotto M, Iwai Y, Honjo T, Gajewski TF 2004 PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells. Cancer Res 64:1140-1145.
47. Hirano F, Kaneko K, Tamura H, Dong H, Wang S, Ichikawa M, Rietz C, Flies DB, Lau JS, Zhu G, Tamada K, Chen L 2005 Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer Res 65:1089-1096.
48. Peggs KS, Quezada SA, Chambers CA, Korman AJ, Allison JP 2009 Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. J Exp Med 206:1717-1725.
49. Hanahan D, Coussens LM 2012 Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell 21:309-322.
50. Tan TT, Coussens LM 2007 Humoral immunity, inflammation and cancer. Curr Opin Immunol 19:209-216.
51. Ji Y, Zhang W 2010 Th17 cells: positive or negative role in tumor?. Cancer Immunol Immunother 59:979-987.
52. Middleton GW, Annels NE, Pandha HS 2012 Are we ready to start studies of Th17 cell manipulation as a therapy for cancer?. Cancer Immunol Immunother 61:1-7.
53. Cunha LL, Ferreira RC, Marcello MA, Vassallo J, Ward LS 2011 Clinical and pathological implications of concurrent autoimmune thyroid disorders and papillary thyroid cancer. J Thyroid Res 2011:387062.
54. Guarino V, Castellone MD, Avilla E, Melillo RM 2010 Thyroid cancer and inflammation. Mol Cell Endocrinol 321:94-102.
55. Matsubayashi S, Kawai K, Matsumoto Y, Mukuta T, Morita T, Hirai K, Matsuzuka F, Kakudoh K, Kuma K, Tamai H 1995 The correlation between papillary thyroid carcinoma and lymphocytic infiltration in the thyroid gland. J Clin Endocrinol Metab 80:3421-3424.
56. Lundgren CI, Hall P, Dickman PW, Zedenius J 2006 Clinically significant prognostic factors for differentiated thyroid carcinoma: a population-based, nested case-control study. Cancer 106:524-531.
57. Kashima K, Yokoyama S, Noguchi S, Murakami N, Yamashita H, Watanabe S, Uchino S, Toda M, Sasaki A, Daa T, Nakayama I 1998 Chronic thyroiditis as a favorable prognostic factor in papillary thyroid carcinoma. Thyroid 8:197-202.
58. Kim EY, Kim WG, Kim WB, Kim TY, Kim JM, Ryu JS, Hong SJ, Gong G, Shong YK 2009 Coexistence of chronic lymphocytic thyroiditis is associated with lower recurrence rates in patients with papillary thyroid carcinoma. Clin Endocrinol (Oxf) 71:581-586.
59. Loh KC, Greenspan FS, Dong F, Miller TR, Yeo PP 1999 Influence of lymphocytic thyroiditis on the prognostic outcome of patients with papillary thyroid carcinoma. J Clin Endocrinol Metab 84:458-463.
60. Ugolini C, Basolo F, Proietti A, Vitti P, Elisei R, Miccoli P, Toniolo A 2007 Lymphocyte and immature dendritic cell infiltrates in differentiated, poorly differentiated, and undifferentiated thyroid carcinoma. Thyroid 17:389-393.
61. French JD, Weber ZJ, Fretwell DL, Said S, Klopper JP, Haugen BR 2010 Tumor-associated lymphocytes and increased FoxP3 + regulatory T cell frequency correlate with more aggressive papillary thyroid cancer. J Clin Endocrinol Metab 95:2325-2333.
62. Melillo RM, Guarino V, Avilla E, Galdiero MR, Liotti F, Prevete N, Rossi FW, Basolo F, Ugolini C, de Paulis A, Santoro M, Marone G 2010 Mast cells have a protumorigenic role in human thyroid cancer. Oncogene 29:6203-6215.
63. Proietti A, Ugolini C, Melillo RM, Crisman G, Elisei R, Santoro M, Minuto M, Vitti P, Miccoli P, Basolo F 2011 Higher intratumoral expression of CD1a, tryptase, and CD68 in a follicular variant of papillary thyroid carcinoma compared to adenomas: correlation with clinical and pathological parameters. Thyroid 21:1209-1215.
64. Barbera-Guillem E, May KF Jr, Nyhus JK, Nelson MB 1999 Promotion of tumor invasion by cooperation of granulocytes and macrophages activated by anti-tumor antibodies. Neoplasia 1:453-460.
65. Gogali F, Paterakis G, Rassidakis GZ, Kaltsas G, Liakou CI, Gousis P, Neonakis E, Manoussakis MN, Liapi C 2012 Phenotypical analysis of lymphocytes with suppressive and regulatory properties (Tregs) and NK cells in the papillary carcinoma of thyroid. J Clin Endocrinol Metab 97:1474-1482.
66. Modi J, Patel A, Terrell R, Tuttle RM, Francis GL 2003 Papillary thyroid carcinomas from young adults and children contain a mixture of lymphocytes. J Clin Endocrinol Metab 88:4418-4425.
67. Xu X, Rao G, Gaffud MJ, Ding HG, Maki G, Klingemann HG, Groh V, Spies T, Caillat-Zucman S, Gattuso P, Plate J, Prinz RA 2006 Clinicopathological significance of major histocompatibility complex class I-related chain a and B expression in thyroid cancer. J Clin Endocrinol Metab 91:2704-2712.
68. Boros P, Balazs G, Szegedi G 1987 Natural killer activity in thyroid cancer patients. Haematologia (Budap) 20:189-193.
69. Qing W, Fang WY, Ye L, Shen LY, Zhang XF, Fei XC, Chen X, WangWQ, Li XY, Xiao JC, Ning G 2012 Density of tumorassociated macrophages correlates with lymph node metastasis in papillary thyroid carcinoma. Thyroid 22:905-910.
70. Ryder M, Ghossein RA, Ricarte-Filho JC, Knauf JA, Fagin JA 2008 Increased density of tumor-associated macrophages is associated with decreased survival in advanced thyroid cancer. Endocr Relat Cancer 15:1069-1074.
71. Caillou B, Talbot M, Weyemi U, Pioche-Durieu C, Al Ghuzlan A, Bidart JM, Chouaib S, Schlumberger M, Dupuy C 2011 Tumor-associated macrophages (TAMs) form an interconnected cellular supportive network in anaplastic thyroid carcinoma. PLoS One 6:e22567.
72. Batistatou A, Zolota V, Scopa CD 2002 S-100 protein + dendritic cells and CD34 + dendritic interstitial cells in thyroid lesions. Endocr Pathol 13:111-115.
73. Scarpino S, Stoppacciaro A, Ballerini F, Marchesi M, Prat M, Stella MC, Sozzani S, Allavena P, Mantovani A, Ruco LP 2000 Papillary carcinoma of the thyroid: hepatocyte growth factor (HGF) stimulates tumor cells to release chemokines active in recruiting dendritic cells. Am J Pathol 156:831-837.
74. Cunha LL, Morari EC, Guihen AC, Razolli D, Gerhard R, Nonogaki S, Soares FA, Vassallo J, Ward LS 2012 Infiltration of a mixture of immune cells may be related to good prognosis in patients with differentiated thyroid carcinoma. Clin Endocrinol (Oxf) 77:918-925.
75. Fiore E, Rago T, Scutari M, Ugolini C, Proietti A, Di Coscio G, Provenzale MA, Berti P, Grasso L, Mariotti S, Pinchera A, Vitti P 2009 Papillary thyroid cancer, although strongly associated with lymphocytic infiltration on histology, is only weakly predicted by serum thyroid auto-antibodies in patients with nodular thyroid diseases. J Endocrinol Invest 32:344-351.
76. Pacini F, Mariotti S, Formica N, Elisei R, Anelli S, Capotorti E, Pinchera A 1988 Thyroid autoantibodies in thyroid cancer: incidence and relationship with tumour outcome. Acta Endocrinol (Copenh) 119:373-380.
77. French JD, Kotnis GR, Said S, Raeburn CD, McIntyre RC Jr, Klopper JP, Haugen BR 2012 Programmed death-1 + T cells and regulatory T cells are enriched in tumor-involved lymph nodes and associated with aggressive features in papillary thyroid cancer. J Clin Endocrinol Metab 97:E934-943.
78. Carrasco J, Godelaine D, Van Pel A, Boon T, van der Bruggen P 2006 CD45RA on human CD8 T cells is sensitive to the time elapsed since the last antigenic stimulation. Blood 108:2897-2905.
79. Jasani B, Wyllie FS, Wright PA, Lemoine NR, Williams ED, Wynford-Thomas D 1990 Immunocytochemically detectable TGF-beta associated with malignancy in thyroid epithelial neoplasia. Growth Factors 2:149-155.
80. Soh EY, Duh QY, Sobhi SA, Young DM, Epstein HD, Wong MG, Garcia YK, Min YD, Grossman RF, Siperstein AE, Clark OH 1997 Vascular endothelial growth factor expression is higher in differentiated thyroid cancer than in normal or benign thyroid. J Clin Endocrinol Metab 82:3741-3747.
81. Stassi G, Todaro M, Zerilli M, Ricci-Vitiani L, Di Liberto D, Patti M, Florena A, Di Gaudio F, Di Gesu G, De Maria R 2003 Thyroid cancer resistance to chemotherapeutic drugs via autocrine production of interleukin-4 and interleukin-10. Cancer Res 63:6784-6790.
82. Wiseman SM, Masoudi H, Niblock P, Turbin D, Rajput A, Hay J, Bugis S, Filipenko D, Huntsman D, Gilks B 2007 Anaplastic thyroid carcinoma: expression profile of targets for therapy offers new insights for disease treatment. Ann Surg Oncol 14:719-729.
83. Mitsiades N, Poulaki V, Mastorakos G, Tseleni-Balafouta ST, Kotoula V, Koutras DA, Tsokos M 1999 Fas ligand expression in thyroid carcinomas: a potential mechanism of immune evasion. J Clin Endocrinol Metab 84:2924-2932.
84. Brown JA, Dorfman DM, Ma FR, Sullivan EL, Munoz O, Wood CR, Greenfield EA, Freeman GJ 2003 Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production. J Immunol 170:1257-1266.
85. Cunha LL, Morari EC, Guihen AC, Razolli D, Gerhard R, Nonogaki S, Soares FA, Vassallo J, Ward LS 2012 Infiltration of a mixture of different immune cells may be related to molecular profile of differentiated thyroid cancer. Endocr Relat Cancer 19:L31-36.
86. Bieche I, Ruffet E, Zweibaum A, Vilde F, Lidereau R, Franc B 1997 MUC1 mucin gene, transcripts, and protein in adenomas and papillary carcinomas of the thyroid. Thyroid 7:725-731.
87. Milkovic M, Sarcevic B, Glavan E 2006 Expression of MAGE tumor-associated antigen in thyroid carcinomas. Endocr Pathol 17:45-52.
88. Ramirez R, Hsu D, Patel A, Fenton C, Dinauer C, Tuttle RM, Francis GL 2000 Over-expression of hepatocyte growth factor/scatter factor (HGF/SF) and the HGF/SF receptor (cMET) are associated with a high risk of metastasis and recurrence for children and young adults with papillary thyroid carcinoma. Clin Endocrinol (Oxf) 53:635-644.
89. Siragusa M, Zerilli M, Iovino F, Francipane MG, Lombardo Y, Ricci-Vitiani L, Di Gesu G, Todaro M, De Maria R, Stassi G 2007 MUC1 oncoprotein promotes refractoriness to chemotherapy in thyroid cancer cells. Cancer Res 67:5522-5530.
90. Nikiforov YE, Nikiforova MN 2011 Molecular genetics and diagnosis of thyroid cancer. Nat Rev Endocrinol 7:569-580.
91. Gedde-Dahl T 3rd, Spurkland A, Eriksen JA, Thorsby E, Gaudernack G 1992 Memory T cells of a patient with follicular thyroid carcinoma recognize peptides derived from mutated p21 ras (Gln/Leu61). Int Immunol 4:1331-1337.
92. Hong DS, Vence L, Falchook G, Radvanyi LG, Liu C, Goodman V, Legos JJ, Blackman S, Scarmadio A, Kurzrock R, Lizee G, Hwu P 2012 BRAF(V600) inhibitor GSK2118436 targeted inhibition of mutant BRAF in cancer patients does not impair overall immune competency. Clin Cancer Res 18:2326-2335.
93. Maio M, Coral S, Sigalotti L, Elisei R, Romei C, Rossi G, Cortini E, Colizzi F, Fenzi G, Altomonte M, Pinchera A, Vitale M 2003 Analysis of cancer/testis antigens in sporadic medullary thyroid carcinoma: expression and humoral response to NY-ESO-1. J Clin Endocrinol Metab 88:748-754.
94. Jo YS, Lee JC, Li S, Choi YS, Bai YS, Kim YJ, Lee IS, Rha SY, Ro HK, Kim JM, Shong M 2008 Significance of the expression of major histocompatibility complex class II antigen, HLA-DR and-DQ, with recurrence of papillary thyroid cancer. Int J Cancer 122:785-790.
95. Le DT, Pardoll DM, Jaffee EM 2010 Cellular vaccine approaches. Cancer J 16:304-310.
96. Higano CS, Schellhammer PF, Small EJ, Burch PA, Nemunaitis J, Yuh L, Provost N, Frohlich MW 2009 Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer 115:3670-3679.
97. Schott M, Seissler J, Lettmann M, Fouxon V, Scherbaum WA, Feldkamp J 2001 Immunotherapy for medullary thyroid carcinoma by dendritic cell vaccination. J Clin Endocrinol Metab 86:4965-4969.
98. Stift A, Sachet M, Yagubian R, Bittermann C, Dubsky P, Brostjan C, Pfragner R, Niederle B, Jakesz R, Gnant M, Friedl J 2004 Dendritic cell vaccination in medullary thyroid carcinoma. Clin Cancer Res 10:2944-2953.
99. Weiner LM, Murray JC, Shuptrine CW 2012 Antibodybased immunotherapy of cancer. Cell 148:1081-1084.
100. Iagaru A, Mittra ES, Ganjoo K, Knox SJ, Goris ML 2010 131I-Tositumomab (Bexxar) vs. 90Y-Ibritumomab (Zevalin) therapy of low-grade refractory/relapsed non-Hodgkin lymphoma. Mol Imaging Biol 12:198-203.
101. Elliott DD, Sherman SI, Busaidy NL, Williams MD, Santarpia L, Clayman GL, El-Naggar AK 2008 Growth factor receptors expression in anaplastic thyroid carcinoma: potential markers for therapeutic stratification. Hum Pathol 39:15-20.
102. Fluge O, Akslen LA, Haugen DR, Varhaug JE, Lillehaug JR 2000 Expression of heregulins and associations with the ErbB family of tyrosine kinase receptors in papillary thyroid carcinomas. Int J Cancer 87:763-770.
103. Murakawa T, Tsuda H, Tanimoto T, Tanabe T, Kitahara S, Matsubara O 2005 Expression of KIT, EGFR, HER-2 and tyrosine phosphorylation in undifferentiated thyroid carcinoma: implication for a new therapeutic approach. Pathol Int 55:757-765.
104. Guth AM, Hafeman SD, Elmslie RE, Dow SW 2012 Liposomal clodronate treatment for tumour macrophage depletion in dogs with soft-tissue sarcoma. Vet Comp Oncol 2012 Apr 27 [Epub ahead of print]; DOI: 10. 1111/j. 1476-5829. 2012. 00319. x.
105. Zeisberger SM, Odermatt B, Marty C, Zehnder-Fjallman AH, Ballmer-Hofer K, Schwendener RA 2006 Clodronateliposome-mediated depletion of tumour-associated macrophages: a new and highly effective antiangiogenic therapy approach. Br J Cancer 95:272-281.
106. Allavena P, Signorelli M, Chieppa M, Erba E, Bianchi G, Marchesi F, Olimpio CO, Bonardi C, Garbi A, Lissoni A, de Braud F, Jimeno J, D'Incalci M 2005 Anti-inflammatory properties of the novel antitumor agent yondelis (trabectedin): inhibition of macrophage differentiation and cytokine production. Cancer Res 65:2964-2971.
107. Monk BJ, Herzog TJ, Kaye SB, Krasner CN, Vermorken JB, Muggia FM, Pujade-Lauraine E, Lisyanskaya AS, Makhson AN, Rolski J, Gorbounova VA, Ghatage P, Bidzinski M, Shen K, Ngan HY, Vergote IB, Nam JH, Park YC, Lebedinsky CA, Poveda AM 2010 Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer. J Clin Oncol 28:3107-3114.
108. Loberg RD, Ying C, Craig M, Day LL, Sargent E, Neeley C, Wojno K, Snyder LA, Yan L, Pienta KJ 2007 Targeting CCL2 with systemic delivery of neutralizing antibodies induces prostate cancer tumor regression in vivo. Cancer Res 67:9417-9424.
109. Qian BZ, Li J, Zhang H, Kitamura T, Zhang J, Campion LR, Kaiser EA, Snyder LA, Pollard JW 2011 CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature 475:222-225.
110. Rolny C, Mazzone M, Tugues S, Laoui D, Johansson I, Coulon C, Squadrito ML, Segura I, Li X, Knevels E, Costa S, Vinckier S, Dresselaer T, Akerud P, De Mol M, Salomaki H, Phillipson M, Wyns S, Larsson E, Buysschaert I, Botling J, Himmelreich U, Van Ginderachter JA, De Palma M, Dewerchin M, Claesson-Welsh L, Carmeliet P 2011 HRG inhibits tumor growth and metastasis by inducing macrophage polarization and vessel normalization through downregulation of PlGF. Cancer Cell 19:31-44.
111. Watkins SK, Egilmez NK, Suttles J, Stout RD 2007 IL-12 rapidly alters the functional profile of tumor-associated and tumor-infiltrating macrophages in vitro and in vivo. J Immunol 178:1357-1362.
112. Beatty GL, Chiorean EG, Fishman MP, Saboury B, Teitelbaum UR, Sun W, Huhn RD, Song W, Li D, Sharp LL, Torigian DA, O'Dwyer PJ, Vonderheide RH 2011 CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science 331:1612-1616.
113. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbe C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ 2010 Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711-723.
114. Camacho LH, Antonia S, Sosman J, Kirkwood JM, Gajewski TF, Redman B, Pavlov D, Bulanhagui C, Bozon VA, Gomez-Navarro J, Ribas A 2009 Phase I/II trial of tremelimumab in patients with metastatic melanoma. J Clin Oncol 27:1075-1081.
115. Kirkwood JM, Lorigan P, Hersey P, Hauschild A, Robert C, McDermott D, Marshall MA, Gomez-Navarro J, Liang JQ, Bulanhagui CA 2010 Phase II trial of tremelimumab (CP-675, 206) in patients with advanced refractory or relapsed melanoma. Clin Cancer Res 16:1042-1048.
116. Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH, Stankevich E, Pons A, Salay TM, McMiller TL, Gilson MM, Wang C, Selby M, Taube JM, Anders R, Chen L, Korman AJ, Pardoll DM, Lowy I, Topalian SL 2010 Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 28:3167-3175.
117. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, Leming PD, Spigel DR, Antonia SJ, Horn L, Drake CG, Pardoll DM, Chen L, Sharfman WH, Anders RA, Taube JM, McMiller TL, Xu H, Korman AJ, Jure-Kunkel M, Agrawal S, McDonald D, Kollia GD, Gupta A, Wigginton JM, Sznol M 2012 Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366:2443-2454.
118. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, Pitot HC, Hamid O, Bhatia S, Martins R, Eaton K, Chen S, Salay TM, Alaparthy S, Grosso JF, Korman AJ, Parker SM, Agrawal S, Goldberg SM, Pardoll DM, Gupta A, Wigginton JM 2012 Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366:2455-2465.
119. de Vries IJ, Castelli C, Huygens C, Jacobs JF, Stockis J, Schuler-Thurner B, Adema GJ, Punt CJ, Rivoltini L, Schuler G, Coulie PG, Lucas S 2011 Frequency of circulating Tregs with demethylated FOXP3 intron 1 in melanoma patients receiving tumor vaccines and potentially Treg-depleting agents. Clin Cancer Res 17:841-848.
120. Morse MA, Hobeika AC, Osada T, Serra D, Niedzwiecki D, Lyerly HK, Clay TM 2008 Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines. Blood 112:610-618.
121. Rech AJ, Vonderheide RH 2009 Clinical use of anti-CD25 antibody daclizumab to enhance immune responses to tumor antigen vaccination by targeting regulatory T cells. Ann NY Acad Sci 1174:99-106.
122. Menard C, Ghiringhelli F, Roux S, Chaput N, Mateus C, Grohmann U, Caillat-Zucman S, Zitvogel L, Robert C 2008 Ctla-4 blockade confers lymphocyte resistance to regulatory T-cells in advanced melanoma: surrogate marker of efficacy of tremelimumab?. Clin Cancer Res 14:5242-5249.
123. Bayry J, Tchilian EZ, Davies MN, Forbes EK, Draper SJ, Kaveri SV, Hill AV, Kazatchkine MD, Beverley PC, Flower DR, Tough DF 2008 In silico identified CCR4 antagonists target regulatory T cells and exert adjuvant activity in vaccination. Proc Natl Acad Sci USA 105:10221-10226.
124. Davies MN, Bayry J, Tchilian EZ, Vani J, Shaila MS, Forbes EK, Draper SJ, Beverley PC, Tough DF, Flower DR 2009 Toward the discovery of vaccine adjuvants: coupling in silico screening and in vitro analysis of antagonist binding to human and mouse CCR4 receptors. PLoS One 4:e8084.
125. Adotevi O, Pere H, Ravel P, Haicheur N, Badoual C, Merillon N, Medioni J, Peyrard S, Roncelin S, Verkarre V, Mejean A, Fridman WH, Oudard S, Tartour E 2010 A decrease of regulatory T cells correlates with overall survival after sunitinib-based antiangiogenic therapy in metastatic renal cancer patients. J Immunother 33:991-998.
126. Balachandran VP, Cavnar MJ, Zeng S, Bamboat ZM, Ocuin LM, Obaid H, Sorenson EC, Popow R, Ariyan C, Rossi F, Besmer P, Guo T, Antonescu CR, Taguchi T, Yuan J, Wolchok JD, Allison JP, DeMatteo RP 2011 Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido. Nat Med 17:1094-1100.
127. Banissi C, Ghiringhelli F, Chen L, Carpentier AF 2009 Treg depletion with a low-dose metronomic temozolomide regimen in a rat glioma model. Cancer Immunol Immunother 58:1627-1634.
128. Gabrilovich DI, Ishida T, Nadaf S, Ohm JE, Carbone DP 1999 Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function. Clin Cancer Res 5:2963-2970.
129. Suzuki H, Onishi H, Wada J, Yamasaki A, Tanaka H, Nakano K, Morisaki T, Katano M 2010 VEGFR2 is selectively expressed by FOXP3high CD4 + Treg. Eur J Immunol 40:197-203.
130. Cohen J 1995 IL-12 deaths: explanation and a puzzle. Science 270:908.
131. Schwartzentruber DJ 2001 Guidelines for the safe administration of high-dose interleukin-2. J Immunother 24:287-293.
132. Suntharalingam G, Perry MR, Ward S, Brett SJ, Castello-Cortes A, Brunner MD, Panoskaltsis N 2006 Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med 355:1018-1028.
133. Vonderheide RH, Flaherty KT, Khalil M, Stumacher MS, Bajor DL, Hutnick NA, Sullivan P, Mahany JJ, Gallagher M, Kramer A, Green SJ, O'Dwyer PJ, Running KL, Huhn RD, Antonia SJ 2007 Clinical activity and immune modulation in cancer patients treated with CP-870, 893, a novel CD40 agonist monoclonal antibody. J Clin Oncol 25:876-883.
134. Fransen MF, Arens R, Melief CJ 2013 Local targets for immune therapy to cancer: Tumor draining lymph nodes and tumor microenvironment. Int J Cancer 132:1971-1976.
135. Cortesina G, De Stefani A, Giovarelli M, Barioglio MG, Cavallo GP, Jemma C, Forni G 1988 Treatment of recurrent squamous cell carcinoma of the head and neck with low doses of interleukin-2 injected perilymphatically. Cancer 62:2482-2485.
136. De Stefani A, Forni G, Ragona R, Cavallo G, Bussi M, Usai A, Badellino F, Cortesina G 2002 Improved survival with perilymphatic interleukin 2 in patients with resectable squamous cell carcinoma of the oral cavity and oropharynx. Cancer 95:90-97.
137. Molenkamp BG, Sluijter BJ, van Leeuwen PA, Santegoets SJ, Meijer S, Wijnands PG, Haanen JB, van den Eertwegh AJ, Scheper RJ, de Gruijl TD 2008 Local administration of PF-3512676 CpG-B instigates tumor-specific CD8 + T-cell reactivity in melanoma patients. Clin Cancer Res 14:4532-4542.
138. Molenkamp BG, van Leeuwen PA, Meijer S, Sluijter BJ, Wijnands PG, Baars A, van den Eertwegh AJ, Scheper RJ, de Gruijl TD 2007 Intradermal CpG-B activates both plasmacytoid and myeloid dendritic cells in the sentinel lymph node of melanoma patients. Clin Cancer Res 13: 2961-2969.
139. Fransen MF, Sluijter M, Morreau H, Arens R, Melief CJ 2011 Local activation of CD8 T cells and systemic tumor eradication without toxicity via slow release and local delivery of agonistic CD40 antibody. Clin Cancer Res 17:2270-2280.
140. Liaw KY, Chang-Chien Y, Chen YC, Deng JS 1980 Impaired cell-mediated